Morphimmune Announces Merger With Immunome and $125 Million Private Investment

San Diego – July 5, 2023 – Cooley advised Morphimmune, a private biotechnology company, on its definitive merger agreement with Immunome. Partners Tom Coll, Barbara Borden and Carlos Ramirez led the Cooley team advising Morphimmune.

Immunome will acquire Morphimmune through a reverse subsidiary merger that is intended to be a tax-free reorganization. The companies also announced an oversubscribed private placement investment of $125 million – with participation from Enavate Sciences, EcoR1 Capital, Redmile Group, Janus Henderson Investors, Avidity Partners, Woodline Partners and other top institutional investors – which will support development of a combined pipeline expected to submit three investigational new drug applications within 18 months of closing. Clay B. Siegall, PhD, current Morphimmune president and CEO, will serve as chairman and CEO of the combined company.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.